Characterization of and risk factors for the acute-phase response after zoledronic acid

I. R. Reid, G. D. Gamble, P. Mesenbrink, P. Lakatos, D. M. Black

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

Context: Intravenous aminobisphosphonates often cause an acute-phase response (APR), but the precise components of this, its frequency, and the risk factors for its development have not been systematically studied. Objective: The objective of the study was to characterize the APR and determine its frequency and the risk factors for its development. Design: The study was an analysis of adverse events from a large randomized trial. Setting: This was a multicenter international trial. Patients: Patients included 7765 postmenopausal women with osteoporosis. Intervention: Zoledronic acid 5 mg annually or placebo was the intervention. Main Outcome Measure: Adverse events occurring within 3 d of zoledronic acid infusion were measured. Results: More than 30 adverse events were significantly more common in the zoledronic acid group and were regarded collectively as constituting an APR. These were clustered into five groups: fever; musculoskeletal (pain and joint swelling); gastrointestinal (abdominal pain, vomiting, diarrhea); eye inflammation; and general (including fatigue, nasopharyngitis, edema). A total of 42.4% of the zoledronic acid group had an APR after the first infusion, compared with 11.7% of the placebo group. All APR components had their peak onset within 1 d, the median duration of the APR was 3 d, and severity was rated as mild or moderate in 90%. Stepwise regression showed that APR was more common in non-Japanese Asians, younger subjects, and nonsteroidal antiinflammatory drug users and was less common in smokers, patients with diabetes, previous users of oral bisphosphonates, and Latin Americans (P <0.05 for all). Conclusion: This analysis identifies new components of the APR and provides the first assessment of risk factors for it. Despite its frequency, APR rarely resulted in treatment discontinuation in this study.

Original languageEnglish
Pages (from-to)4380-4387
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume95
Issue number9
DOIs
Publication statusPublished - 2010

Fingerprint

zoledronic acid
STAT3 Transcription Factor
Acute-Phase Reaction
Diphosphonates
Medical problems
Swelling
Anti-Inflammatory Agents
Fatigue of materials
Nasopharyngitis
Placebos
Musculoskeletal Pain
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Characterization of and risk factors for the acute-phase response after zoledronic acid. / Reid, I. R.; Gamble, G. D.; Mesenbrink, P.; Lakatos, P.; Black, D. M.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 95, No. 9, 2010, p. 4380-4387.

Research output: Contribution to journalArticle

Reid, I. R. ; Gamble, G. D. ; Mesenbrink, P. ; Lakatos, P. ; Black, D. M. / Characterization of and risk factors for the acute-phase response after zoledronic acid. In: Journal of Clinical Endocrinology and Metabolism. 2010 ; Vol. 95, No. 9. pp. 4380-4387.
@article{5647b99385f941c6a14c23c980a31e3f,
title = "Characterization of and risk factors for the acute-phase response after zoledronic acid",
abstract = "Context: Intravenous aminobisphosphonates often cause an acute-phase response (APR), but the precise components of this, its frequency, and the risk factors for its development have not been systematically studied. Objective: The objective of the study was to characterize the APR and determine its frequency and the risk factors for its development. Design: The study was an analysis of adverse events from a large randomized trial. Setting: This was a multicenter international trial. Patients: Patients included 7765 postmenopausal women with osteoporosis. Intervention: Zoledronic acid 5 mg annually or placebo was the intervention. Main Outcome Measure: Adverse events occurring within 3 d of zoledronic acid infusion were measured. Results: More than 30 adverse events were significantly more common in the zoledronic acid group and were regarded collectively as constituting an APR. These were clustered into five groups: fever; musculoskeletal (pain and joint swelling); gastrointestinal (abdominal pain, vomiting, diarrhea); eye inflammation; and general (including fatigue, nasopharyngitis, edema). A total of 42.4{\%} of the zoledronic acid group had an APR after the first infusion, compared with 11.7{\%} of the placebo group. All APR components had their peak onset within 1 d, the median duration of the APR was 3 d, and severity was rated as mild or moderate in 90{\%}. Stepwise regression showed that APR was more common in non-Japanese Asians, younger subjects, and nonsteroidal antiinflammatory drug users and was less common in smokers, patients with diabetes, previous users of oral bisphosphonates, and Latin Americans (P <0.05 for all). Conclusion: This analysis identifies new components of the APR and provides the first assessment of risk factors for it. Despite its frequency, APR rarely resulted in treatment discontinuation in this study.",
author = "Reid, {I. R.} and Gamble, {G. D.} and P. Mesenbrink and P. Lakatos and Black, {D. M.}",
year = "2010",
doi = "10.1210/jc.2010-0597",
language = "English",
volume = "95",
pages = "4380--4387",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "9",

}

TY - JOUR

T1 - Characterization of and risk factors for the acute-phase response after zoledronic acid

AU - Reid, I. R.

AU - Gamble, G. D.

AU - Mesenbrink, P.

AU - Lakatos, P.

AU - Black, D. M.

PY - 2010

Y1 - 2010

N2 - Context: Intravenous aminobisphosphonates often cause an acute-phase response (APR), but the precise components of this, its frequency, and the risk factors for its development have not been systematically studied. Objective: The objective of the study was to characterize the APR and determine its frequency and the risk factors for its development. Design: The study was an analysis of adverse events from a large randomized trial. Setting: This was a multicenter international trial. Patients: Patients included 7765 postmenopausal women with osteoporosis. Intervention: Zoledronic acid 5 mg annually or placebo was the intervention. Main Outcome Measure: Adverse events occurring within 3 d of zoledronic acid infusion were measured. Results: More than 30 adverse events were significantly more common in the zoledronic acid group and were regarded collectively as constituting an APR. These were clustered into five groups: fever; musculoskeletal (pain and joint swelling); gastrointestinal (abdominal pain, vomiting, diarrhea); eye inflammation; and general (including fatigue, nasopharyngitis, edema). A total of 42.4% of the zoledronic acid group had an APR after the first infusion, compared with 11.7% of the placebo group. All APR components had their peak onset within 1 d, the median duration of the APR was 3 d, and severity was rated as mild or moderate in 90%. Stepwise regression showed that APR was more common in non-Japanese Asians, younger subjects, and nonsteroidal antiinflammatory drug users and was less common in smokers, patients with diabetes, previous users of oral bisphosphonates, and Latin Americans (P <0.05 for all). Conclusion: This analysis identifies new components of the APR and provides the first assessment of risk factors for it. Despite its frequency, APR rarely resulted in treatment discontinuation in this study.

AB - Context: Intravenous aminobisphosphonates often cause an acute-phase response (APR), but the precise components of this, its frequency, and the risk factors for its development have not been systematically studied. Objective: The objective of the study was to characterize the APR and determine its frequency and the risk factors for its development. Design: The study was an analysis of adverse events from a large randomized trial. Setting: This was a multicenter international trial. Patients: Patients included 7765 postmenopausal women with osteoporosis. Intervention: Zoledronic acid 5 mg annually or placebo was the intervention. Main Outcome Measure: Adverse events occurring within 3 d of zoledronic acid infusion were measured. Results: More than 30 adverse events were significantly more common in the zoledronic acid group and were regarded collectively as constituting an APR. These were clustered into five groups: fever; musculoskeletal (pain and joint swelling); gastrointestinal (abdominal pain, vomiting, diarrhea); eye inflammation; and general (including fatigue, nasopharyngitis, edema). A total of 42.4% of the zoledronic acid group had an APR after the first infusion, compared with 11.7% of the placebo group. All APR components had their peak onset within 1 d, the median duration of the APR was 3 d, and severity was rated as mild or moderate in 90%. Stepwise regression showed that APR was more common in non-Japanese Asians, younger subjects, and nonsteroidal antiinflammatory drug users and was less common in smokers, patients with diabetes, previous users of oral bisphosphonates, and Latin Americans (P <0.05 for all). Conclusion: This analysis identifies new components of the APR and provides the first assessment of risk factors for it. Despite its frequency, APR rarely resulted in treatment discontinuation in this study.

UR - http://www.scopus.com/inward/record.url?scp=77956566798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956566798&partnerID=8YFLogxK

U2 - 10.1210/jc.2010-0597

DO - 10.1210/jc.2010-0597

M3 - Article

C2 - 20554708

AN - SCOPUS:77956566798

VL - 95

SP - 4380

EP - 4387

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 9

ER -